This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Longeveron, Inc.. Active years: 2024-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2025
Title: Innovations by Ana Marie Landin
Introduction
Ana Marie Landin is a prominent inventor based in Miami, FL (US). She has made significant contributions to the field of regenerative medicine, particularly through her work with mesenchymal stem cells. With a total of 2 patents, her innovations focus on addressing aging frailty and enhancing immune responses.
Latest Patents
One of her latest patents is titled "Method of treating aging frailty in subjects with inflammaging using human mesenchymal stem cells." This invention provides a method for treating subjects with non-ischemic dilated cardiomyopathy by administering a therapeutically effective amount of an isolated population of allogeneic human mesenchymal stem cells. Additionally, it offers a method for treating symptoms of aging frailty using the same type of stem cells. Another notable patent is "Mesenchymal stem cells as vaccine adjuvants and methods for using the same." This invention enhances immune responses to vaccines by administering a vaccine alongside a population of isolated allogeneic human mesenchymal stem cells. It also includes kits that contain a vaccine in one container and the stem cells in another.
Career Highlights
Ana Marie Landin is associated with Longeveron, Inc., a company dedicated to developing innovative therapies using stem cell technology. Her work has been instrumental in advancing the understanding and application of mesenchymal stem cells in clinical settings.
Conclusion
Ana Marie Landin's contributions to the field of regenerative medicine through her patents highlight her innovative spirit and dedication to improving health outcomes. Her work continues to pave the way for new treatments that address aging and immune response challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile